These findings suggest that pharmacological KV7.4 activation holds great potential as a novel therapeutic approach for ARHL by preventing or decelerating age-related decline of auditory function and morphological loss of OHCs, as well as for other hearing impairments related to compromised KV7.4 function. This evidence concerns the gene KCNQ4 and Hearing impairment.